Sponsor:
Mel Mont Medical
Code:
NCT07758140
Conditions
HPV
HPV - Anogenital Human Papilloma Virus Infection
Eligibility Criteria
Sex: Female
Age: 25 - 65
Healthy Volunteers: Accepted
Interventions
Mia by XytoTest
Rovers Cervex-Brush
Brief summary:
Conditions
HPV
HPV - Anogenital Human Papilloma Virus Infection
Study ID
NCT07758140
Start date
Jul 9, 2026
Status verified date
Aug, 2026
Completion date
Sep, 2026
Anticipated
Primary completion date
Aug, 2026
Anticipated
Eligibility Criteria
Sex: Female
Age: 25 - 65
Healthy Volunteers: Accepted
Enrollment
260 participants
Anticipated
Allocation
Non randomized
Intervention Model
Parallel Assignment
Primary purpose
Screening
Arms
active comparator: General Population Group
active comparator: Enriched Population Group
Interventions
Mia by XytoTest
Rovers Cervex-Brush
Primary outcome measure
Central contacts
Locations
ASR Arizona CGA
Recruiting
Phoenix, Arizona, United States, 85004
Contacts
Integrated Clinical Research
Recruiting
Sherman Oaks, California, United States, 91403
Contacts
Altus Clinical Research
Recruiting
Lake Worth, Florida, United States, 33461
Contacts
Zenacare Research
Recruiting
North Miami Beach, Florida, United States, 33169
Contacts
ASR Idaho CGI
Recruiting
Boise, Idaho, United States, 83702
Contacts
Boeson Research - Great Falls
Recruiting
Great Falls, Montana, United States, 59405
Contacts
Unified Women's Clinical Research
Recruiting
Raleigh, North Carolina, United States, 27607
Contacts
Innovo-Wilmington Health
Recruiting
Wilmington, North Carolina, United States, 28401
Contacts
Lyndhurst Clinical Research (Unified)
Recruiting
Winston-Salem, North Carolina, United States, 27103
Contacts
Amie Butler
336-765-9350El Centro de Corazon
Recruiting
Houston, Texas, United States, 77012
Contacts
National Eagle Research
Recruiting
Lynnwood, Washington, United States, 98036
Contacts
Sponsor
Mel Mont Medical
Last update posted
Aug 11, 2026
Last verified
Aug, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-03. This information was provided to ClinicalTrials.gov by Mel Mont Medical on 2026-08-11.